Bevetex 100mg Injection is a targeted therapy used in the treatment of certain types of cancer. Its active ingredient is Bevacizumab, a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). By blocking VEGF, Bevetex prevents the formation of new blood vessels that tumors need to grow and survive. This mechanism, known as anti-angiogenesis, helps to slow down or stop tumor progression.
Bevetex 100mg Injection is indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and advanced cervical cancer, often in combination with chemotherapy. The dosage and administration schedule are determined by the prescribing physician based on the specific cancer type, stage, and the patient’s overall health.
Common side effects may include hypertension, proteinuria, fatigue, and gastrointestinal issues. Less common but serious side effects can involve bleeding, wound healing complications, and arterial thromboembolic events. Patients should inform their doctor of any pre-existing medical conditions, especially cardiovascular issues or recent surgery. Bevetex 100mg Injection should be stored at controlled room temperature, protected from light, and should not be frozen. It is administered intravenously.
